About the National Data

Data

Baseline: 12.4 percent of Medicare beneficiaries aged 18 to 75 years with sickle cell anemia received disease modifying therapies in accordance with the National Heart, Lung, and Blood Institute (NHLBI)'s guidelines in 2016

Target: 15.9 percent

Numerator
Number of Medicare beneficiaries aged 18 to 75 years with sickle cell anemia using hydroxyurea.
Denominator
Number of Medicare beneficiaries aged 18 to 75 years with sickle cell anemia.
Target-setting method

Percentage point improvement

Target-setting method details
Percentage point improvement from the baseline using Cohen's h effect size of 0.10.
Target-setting method justification
Trend data were not available for this objective. A percentage point improvement was calculated using Cohen's h effect size of 0.1. This method was used because no standard error value was available and while sickle cell disease is the most common inherited blood disorder in the United States, it is a rare disease.

History

Comparable HP2020 objective
Related, which includes objectives that have the same or a similar intent to either a measurable or developmental/archived objective in HP2020.